Marco Dioguardi Burgio
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
A deep learning algorithm achieved liver metastasis detection rates on contrast-enhanced abdominal CT scans comparable to those of radiologists, with consistent performance across different lesion sizes, locations, and clinical conditions.
Year:
2026
Year:
2026
Background and Aims: Noninvasive tools assessing steatosis, such as ultrasonography-based 2D-attenuation imaging (ATI), are needed to tackle the worldwide burden of steatotic liver disease. This one-stage individual patient data (IPD) meta-analysis aimed to create an ATI-based steatosis grading system. Approach and Results: A systematic review (EMBASE + MEDLINE, 2018–2022) identified studies, including patients with histologically or magnetic resonance imaging proton-density fat fraction (MRI-PDFF)–verified ATI for grading steatosis (S0 to S3). One-stage IPD meta-analyses were conducted using generalized mixed models with a random study-specific intercept. Created ATI-based steatosis grading system (aS0 to aS3) was externally validated on a prospective cohort of patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (n=174, histologically and MRI-PDFF–verified steatosis). Eleven enrolled studies included 1374 patients, classified into S0, S1, S2, and S3 in 45.4%, 35.0%, 9.3%, and 10.3% of the cases. ATI was correlated with histological steatosis ( r = 0.60; 95% CI: 0.52, 0.67; p < 0.001) and MRI-PDFF ( r = 0.70; 95% CI: 0.66, 0.73; p < 0.001) but not with liver stiffness ( r = 0.03; 95% CI: −0.04, 0.11, p = 0.343). Steatosis grade was an independent factor associated with ATI (coefficient: 0.24; 95% CI: [0.22, 0.26]; p < 0.001). ATI marginal means within S0, S1, S2, and S3 subpopulations were 0.59 (95% CI: [0.58, 0.61]), 0.69 (95% CI [0.67, 0.71]), 0.78 (95% CI: [0.76, 0.81]), and 0.85 (95% CI: [0.83, 0.88]) dB/cm/MHz; all contrasts between grades were significant ( p < 0.0001). Three ATI thresholds were calibrated to create a new ATI-based steatosis grading system (aS0 to aS3, cutoffs: 0.66, 0.73, and 0.81 dB/cm/MHz). Its external validation showed Obuchowski measures of 0.84 ± 0.02 and 0.82 ± 0.02 with histologically based and MRI-PDFF–based references. Conclusions: ATI is a reliable, noninvasive marker of steatosis. This validated ATI-based steatosis grading system could be valuable in assessing patients with metabolic dysfunction–associated steatotic liver disease.
Year:
2025
This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), are emerging as leading causes of hepatocellular carcinoma (HCC) development. This has important implications for evaluating patients with these conditions, including the potential for early diagnosis through screening techniques. Imaging techniques for the noninvasive diagnosis of HCC in the context of MASLD also present unique considerations. Notably, HCC development in patients without cirrhosis is more frequent in MASLD compared to other chronic liver disease etiologies. Moreover, the presence of liver steatosis, a common feature in MASLD patients, can modify the radiological appearance of the liver, giving HCC in MASLD/MASH uncommon imaging characteristics. Additionally, certain histological subtypes, particularly the steatohepatitic HCC, are more prevalent in MASLD/MASH, which may influence both diagnostic strategies and therapeutic decisions in these patients. This review article focuses on the radiological characteristics of HCC developed in patients with MASLD/MASH. It specifically addresses the roles of screening and surveillance, the radiological features of HCC in MASLD/MASH, the histological subtypes associated with these conditions, and the impact of imaging on treatment decisions. Finally, a brief summary of future directions and the role of new technologies in HCC diagnosis within the context of MASLD is provided.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (14)
Lucia Parlati
Assistance Publique - Hôpitaux de Paris
Christian B. van der Pol
-
Anita Paisant
-
Thomas Karlas
University Hospital Leipzig
Jeong Min Lee
Professor
Seoul National University College of Medicine
Hyo-Jin Kang
Seoul National University Hospital
Philip Newsome
Director of Roger Williams Institute of Liver Studies
University of Birmingham
Federica Vernuccio
Docenti di ruolo di IIa fascia
University of Palermo
Andreu Costa
college of pharmacy dalhousie university halifax nova scotia canada
Cédric LAOUENAN
Professor
Université Paris-Saclay
Florent Besson
Professor (PU-PH)
Université Paris-Saclay
Emmanuel Tsochatzis
Professor of Hepatology and Consultant Hepatologist
University College London
Christian Hobeika
MCU-PH
Assistance Publique - Hôpitaux de Paris
Edward Grant
Professor
University of Southern California
Make your next move.
Prepare your application
Review drafts before you send them.